NHS, the National Cancer Research Institution (NCRI) and the National Cancer Registration and Analysis Service (NCRAS) 1. ENETs Centres of Excellence and expert neuroendocrine multidisciplinary teams 2. Medical and nursing societies 3. Advocacy organisations such as Cancer 52 and the International Neuroendocrine Cancer Alliance (INCA) 4. Political/ Policy agencies both in the UK, Europe and Internationally 5. Pharmaceutical industry 6. The MRT Consortium 7. Some examples are further work on the Ideal Patient Pathway, further development of our Spotlight Campaign including a new education hub for HCPs, launch of our new patient web guides and monthly educational webinars, a face- to-face educational event and continued collaboration on various projects to improve the collation of important data, understanding and awareness about neuroendocrine cancers. Some of these collaborations include:
Looking ahead to the next 5 years, the adaptations to our strategic approach will allow us to drive forward with our 4 main priorities:
Empower and support more people affected by neuroendocrine cancer
Educate a wider audience with reliable, accurate, and data driven information
Effectively raise awareness of neuroendocrine cancer to a defined and relevant audience
Invest in research, through funding of a balanced & broad research programme
We were founded by patients, families & HCP’s, therefore we will continue to listen and respond to the needs of our community as a primary objective; the voice of those affected directly by neuroendocrine cancer will remain at the heart of any decisions around our future.
Made with FlippingBook - Online magazine maker